{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:29:02Z","timestamp":1793946542738,"version":"4.8.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004896","name":"Eisai Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004896","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.eclinm.2026.104206","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:16:26Z","timestamp":1790198186000},"page":"104206","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["E7386 plus lenvatinib in patients with advanced endometrial cancer that progressed on platinum-based chemotherapy and an anti-PD-(L)1 immunotherapy: a single-arm, open-label, global phase 1b\/2 dose-expansion cohort"],"prefix":"10.1016","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7948-1350","authenticated-orcid":false,"given":"Jung-Yun","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosei","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byoung-Gie","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Berman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley","family":"Corr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayu","family":"Yunokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Orr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0787-2851","authenticated-orcid":false,"given":"Noboru","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela T.","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8215-5887","authenticated-orcid":false,"given":"David S.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1877-0172","authenticated-orcid":false,"given":"Alka A.","family":"Potdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takatoshi","family":"Sahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2553-3076","authenticated-orcid":false,"given":"Takayuki","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jincao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodi","family":"McKenzie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrisann","family":"Kyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2026.104206_bib2","first-page":"258","article-title":"Current recommendations and recent progress in endometrial cancer","volume":"69","author":"Brooks","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.eclinm.2026.104206_bib3","doi-asserted-by":"crossref","first-page":"651","DOI":"10.2147\/IJWH.S499435","article-title":"Global trends in incidence and mortality rates of endometrial cancer among individuals aged 55 years and above from 1990 to 2021: an analysis of the global burden of disease","volume":"17","author":"Gao","year":"2025","journal-title":"Int J Womens Health"},{"key":"10.1016\/j.eclinm.2026.104206_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102790","article-title":"Locally advanced and metastatic endometrial cancer: current and emerging therapies","volume":"129","author":"Salmon","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.eclinm.2026.104206_bib5","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41572-021-00324-8","article-title":"Endometrial cancer","volume":"7","author":"Makker","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.eclinm.2026.104206_bib6","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.104206_bib8","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.104206_bib9","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ygyno.2015.04.026","article-title":"Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer","volume":"138","author":"McMeekin","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.eclinm.2026.104206_bib10","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1200\/JCO.22.02152","article-title":"Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: updated efficacy and safety from the randomized phase III study 309\/KEYNOTE-775","volume":"41","author":"Makker","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2026.104206_bib11","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ijc.23131","article-title":"E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition","volume":"122","author":"Matsui","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.eclinm.2026.104206_bib12","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.canlet.2013.07.007","article-title":"Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models","volume":"340","author":"Okamoto","year":"2013","journal-title":"Cancer Lett"},{"key":"10.1016\/j.eclinm.2026.104206_bib13","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/638747","article-title":"Antitumor activity of lenvatinib (E7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models","volume":"2014","author":"Tohyama","year":"2014","journal-title":"J Thyroid Res"},{"key":"10.1016\/j.eclinm.2026.104206_bib14","series-title":"Lenvima (Lenvatinib) [Prescribing Information]","year":"2025"},{"key":"10.1016\/j.eclinm.2026.104206_bib15","series-title":"Lenvima 4 mg Hard Capsules [Summary of Product Characteristics]","year":"2025"},{"key":"10.1016\/j.eclinm.2026.104206_bib16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2026.104206_bib17","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1200\/JCO.23.02767","article-title":"Efficacy and safety of sacituzumab govitecan in patients with advanced solid tumors (TROPiCS-03): analysis in patients with advanced endometrial cancer","volume":"42","author":"Santin","year":"2024","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.eclinm.2026.104206_bib18","article-title":"Rinatabart sesutecan (Rina-S\u00ae) for patients with advanced or recurrent endometrial cancer (a\/r EC): update from dose expansion cohort B2 of RAINFOL\u2122-01 [abstract]","volume":"36","author":"Cloven","year":"2025","journal-title":"Ann Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.eclinm.2026.104206_bib19","doi-asserted-by":"crossref","first-page":"S693","DOI":"10.1016\/j.annonc.2025.08.1748","article-title":"Sacituzumab tirumotecan (Sac-TMT) monotherapy in advanced\/metastatic endometrial carcinoma (EC): results from a phase I\/II study (MK-2870-001\/KL264-01) [abstract]","volume":"36","author":"Wang","year":"2025","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.eclinm.2026.104206_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.102654","article-title":"A randomized, phase III study of sacituzumab govitecan versus treatment of the physician's choice in patients with endometrial cancer after platinum-based chemotherapy and immunotherapy: the ASCENT-GYN-01 study (GOG-3104\/ENGOT-en26\/APGOT-EN2)","volume":"36","author":"Eskander","year":"2026","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.eclinm.2026.104206_bib21","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.3390\/cancers15041278","article-title":"Mechanisms of resistance to antibody-drug conjugates","volume":"15","author":"Abelman","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.eclinm.2026.104206_bib22","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1158\/0008-5472.CAN-20-0782","article-title":"E7386, a selective inhibitor of the interaction between \u03b2-catenin and CBP, exerts antitumor activity in tumor models with activated canonical Wnt signaling","volume":"81","author":"Yamada","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.eclinm.2026.104206_bib23","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.1158\/1078-0432.CCR-25-0725","article-title":"E7386 enhances lenvatinib's antitumor activity in preclinical models and human hepatocellular carcinoma","volume":"31","author":"Mesropian","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"7 Suppl","key":"10.1016\/j.eclinm.2026.104206_bib24","doi-asserted-by":"crossref","first-page":"7171","DOI":"10.1158\/1538-7445.AM2026-7171","article-title":"Antitumor and antiangiogenic activities of E7386 in combination with lenvatinib in human endometrial carcinoma xenograft models [abstract]","volume":"86","author":"Adachi","year":"2026","journal-title":"Cancer Res"},{"issue":"Suppl 9","key":"10.1016\/j.eclinm.2026.104206_bib25","doi-asserted-by":"crossref","first-page":"S1598","DOI":"10.1016\/j.annonc.2022.10.432","article-title":"A phase Ib study of E7386, a CREB-binding protein (CBP)\/\u03b2-catenin interaction inhibitor, in combination with lenvatinib in patients (pts) with advanced solid tumors [abstract]","volume":"33","author":"Kondo","year":"2022","journal-title":"Ann Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.eclinm.2026.104206_bib26","article-title":"Global, phase Ib dose-expansion cohort of E7386 + lenvatinib (LEN) in patients (pts) with advanced (a) endometrial cancer (EC) that progressed on platinum-based chemotherapy (CTx) and an anti-PD-(L)1 immunotherapy (IO) [abstract]","volume":"35","author":"Lee","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2026.104206_bib27","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/jnci\/djp079","article-title":"Dose escalation methods in phase I cancer clinical trials","volume":"101","author":"Le Tourneau","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"7 Suppl","key":"10.1016\/j.eclinm.2026.104206_bib28","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1158\/1538-7445.AM2023-1830","volume":"83","author":"Kawano","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.eclinm.2026.104206_bib29","doi-asserted-by":"crossref","first-page":"7490","DOI":"10.1158\/1078-0432.CCR-17-2157","article-title":"A first-in-human phase I study of the anticancer stem cell agent ipafricept (OMP-54F28), a decoy receptor for Wnt ligands, in patients with advanced solid tumors","volume":"23","author":"Jimeno","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eclinm.2026.104206_bib30","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s10637-019-00824-1","article-title":"A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer","volume":"38","author":"Davis","year":"2020","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.eclinm.2026.104206_bib31","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ygyno.2019.12.039","article-title":"Second-line lenvatinib in patients with recurrent endometrial cancer","volume":"156","author":"Vergote","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.eclinm.2026.104206_bib32","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ygyno.2023.03.013","article-title":"DKK1 is a predictive biomarker for response to DKN-01: results of a phase 2 basket study in women with recurrent endometrial carcinoma","volume":"172","author":"Arend","year":"2023","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.eclinm.2026.104206_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/ijms27021096","article-title":"Molecular landscape of advanced endometrial cancer: exploratory analyses at Modena Cancer Center (MEMO)","volume":"27","author":"Pirola","year":"2026","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.eclinm.2026.104206_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105893","article-title":"E7386 in patients with advanced solid tumors: results from the dose-escalation part and an expansion part of a phase 1 study","volume":"10","author":"Kondo","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.eclinm.2026.104206_bib35","article-title":"Randomized study evaluating optimal dose, efficacy, and safety of E7386 plus lenvatinib versus treatment of physician's choice in advanced\/recurrent endometrial carcinoma previously treated with platinum-based chemotherapy and immune checkpoint inhibitors","volume":"35","author":"Eskander","year":"2025","journal-title":"Int J Gynecol Cancer"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026004591?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026004591?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:48:44Z","timestamp":1793944124000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537026004591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":33,"alternative-id":["S2589537026004591"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.104206","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"E7386 plus lenvatinib in patients with advanced endometrial cancer that progressed on platinum-based chemotherapy and an anti-PD-(L)1 immunotherapy: a single-arm, open-label, global phase 1b\/2 dose-expansion cohort","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.104206","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Eisai Inc. and The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104206"}}